THE Winifred Masterson Burke Rehabilitation Hospital

Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer’s. His research culminated in the Benfoteam clinical trial evaluating benfotiamine, a thiamine precursor, for slowing Alzheimer’s progression. The trial aims to determine the highest safe dose and its efficacy in improving cognition and global function.

Dr. Gary Gibson hypothesizes that thiamine deficiency alters glucose metabolism in brain cells, leading to Alzheimer's. His research led to a nationwide clinical trial evaluating benfotiamine, an oral drug boosting thiamine levels, as a potential treatment.

A national clinical trial, funded by the NIH, is testing a synthetic vitamin B1 (benfotiamine) developed by Burke Neurological Institute for treating mild cognitive impairment and early Alzheimer's disease. The trial, involving 50 sites across the U.S., aims to evaluate benfotiamine's effects on cognitive function and its potential to slow cognitive decline in participants aged 50-89. The study builds on research showing benfotiamine's ability to improve memory and reduce plaques, tangles, inflammation, and oxidative stress in animal models.

A national clinical trial, funded by NIH, tests benfotiamine, a synthetic vitamin B1, for treating mild cognitive impairment and early Alzheimer's disease. The trial, led by Burke Neurological Institute, UC San Diego, and Columbia University, aims to evaluate benfotiamine's cognitive effects and safety profile. Enrollment targets 406 participants aged 50-89 across 50 U.S. sites.